|1.||Combs, Gerald F: 5 articles (10/2014 - 02/2003)|
|2.||Sinha, Raghu: 5 articles (08/2014 - 04/2007)|
|3.||El-Bayoumy, Karam: 5 articles (08/2014 - 01/2003)|
|4.||Goulet, Anne-Christine: 5 articles (04/2007 - 07/2002)|
|5.||Nelson, Mark A: 5 articles (04/2007 - 07/2002)|
|6.||Minasian, Lori M: 4 articles (01/2014 - 04/2006)|
|7.||Lippman, Scott M: 4 articles (11/2011 - 07/2005)|
|8.||Marshall, James R: 4 articles (11/2011 - 04/2006)|
|9.||Lü, Junxuan: 4 articles (01/2011 - 05/2008)|
|10.||Thompson, Ian M: 3 articles (09/2014 - 04/2006)|
04/01/2009 - "Protective effects of selenomethionine against ionizing radiation under the modulation of p53 tumor suppressor."
01/01/2008 - "The present study was undertaken to examine the effects of L-selenomethionine (SeM), a potential cancer chemopreventive agent, on the gene expression profile of the cultured cell clones. "
01/01/2014 - "Currently, selenomethionine is also used as a prodrug in cancer therapy along with enzyme methionase that converts prodrug into active toxic chemical(s) that causes death of cancerous cells/tissue. "
05/01/2013 - "The organic Se compounds (particularly selenomethionine [SeMet]) in plants and yeasts are very effective chemoprotectants for mammalian cancer. "
02/01/2006 - "Tumor-selective killing was not observed in cells treated with selenomethionine. "
|2.||Prostatic Neoplasms (Prostate Cancer)
04/01/2006 - "We conducted a randomized, controlled, short-term trial of l-selenomethionine (SeMet) versus observation in men with organ-confined prostate cancer. "
01/01/2006 - "Even though many studies have consistently shown that selenomethionine is an ineffective anticarcinogen at doses corresponding to those currently allowed by the FDA, it has been chosen as the Se intervention agent in the 32,500-man (phase III), NCI-funded SELECT trial, which tests the effectiveness of dietary supplements of dietary supplements of Se and tocopherol, individually or in combination, in the prevention of prostate cancer. "
09/01/2014 - "A positive plasma α-tocopherol-prostate cancer association also seemed limited to high-grade disease (Gleason grade, 7-10; overall Q5 HR, 1.59; 95% CI, 1.13-2.24; P-trend = 0.001; among men receiving selenomethionine, Q5 HR, 2.12; 95% CI, 1.32-3.40; P-trend = 0.0002). "
09/01/2014 - "Incidence of prostate cancer as a function of plasma α-tocopherol, γ-tocopherol, and supplementation with α-tocopherol or selenomethionine was estimated by the hazard ratio (HR). "
02/01/2007 - "Selenomethionine induced transcriptional programs in human prostate cancer cells."
|3.||Skin Neoplasms (Skin Cancer)
10/01/2014 - "The effects of topical L-selenomethionine on protection against UVB-induced skin cancer when given before, during, and after UVB exposure."
10/01/2014 - "Previous studies in mice have shown that topical L-selenomethionine (SeMet) can prevent UVB-induced skin cancer when applied continuously before, during, and after the radiation exposure. "
01/01/1992 - "The effects of topical and oral L-selenomethionine on pigmentation and skin cancer induced by ultraviolet irradiation."
09/01/2003 - "In protecting against skin cancer, topical Eol and topical L-selenomethionine plus oral Eac were best. "
09/01/2003 - "Effects of topical L-selenomethionine with topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh:2 hairless mice."
|4.||Colonic Neoplasms (Colon Cancer)
05/01/2006 - "In the present study we tested the hypothesis that selenomethionine might affect colon cancer cell growth by p53 mediated apoptosis and/or cell cycle regulation. "
11/01/2005 - "Studies into the anticancer effects of selenomethionine against human colon cancer."
04/01/2007 - "Profiling of selenomethionine responsive genes in colon cancer by microarray analysis."
05/01/2006 - "These results clearly suggest that selenomethionine exerts p53 dependent growth inhibitory effects in colon cancer cells by inducing G2/M cell cycle arrest as well as apoptosis."
05/01/2006 - "Four human colon cancer cell lines including HCT116 and RKO (wild type p53), HCT116-p53KO (isogenic control of HCT116 cells with p53 knocked out) and Caco-2 (mutant p53) were treated with 0-100 microM of selenomethionine for 24, 48 and 72 h. "
|5.||Melanoma (Melanoma, Malignant)
03/01/1999 - "The present study investigated the effect of dietary supplementation of selenomethionine on pulmonary metastasis of B16BL6 murine melanoma cells in C57BL/6 mice. "
03/01/2013 - "In vivo, we used the HGF transgenic mouse model of UV-induced melanoma to demonstrate that topical treatment with l-selenomethionine results in a significant delay in the time required for UV-induced melanoma development, but also increases the rate of growth of those tumors once they appear. "
03/01/1999 - "Dietary supplementation of selenomethionine reduces metastasis of melanoma cells in mice."
03/01/1999 - "These results demonstrate that dietary supplementation of selenomethionine reduced experimental metastasis of melanoma cells in mice and inhibited the growth of metastatic tumors that formed in the lungs. "
03/13/1998 - "Selenomethionine was tested against each of three human tumor cell lines (MCF-7/S breast carcinoma, DU-145 prostate cancer cells and UACC-375 melanoma) and against normal human diploid fibroblasts. "
|2.||Sodium Selenite (Selenite)
|6.||DNA (Deoxyribonucleic Acid)
|7.||selenic acid (selenate)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Gamma Cameras (Gamma Camera)
|5.||Transplantation (Transplant Recipients)